Sofie Biosciences was ensured an additional $2 million from new and existing investors. The capital will be applied to the development of new PET imaging agents and to enhance its existing PET imaging systems and chemistry units.
Sofie Biosciences is developing molecular imaging agents to enable earlier and more accurate diagnosis, treatment selection, and therapeutic monitoring of major medical disorders. The firm combines PET imaging agents with innovative imaging systems to provide researchers and physicians with tools to better investigate the biology of disease.
The company’s primary products revolve around PET imaging. Its Genisys technology is reportedly a high-performance, benchtop, cost-effective system for use in preclinical experiments. The 18F-FAC and analogs are Sofie’s family of PET probes that allow investigators to examine a class of biological processes in oncology, immunology, and pharmacology.
The 18F-FAC product was created under an exclusive license from the University of California, which had developed FAC as a family of PET molecular imaging agents. FAC has been shown in preclinical animal research and early patient studies to have promise as a whole-body noninvasive means of determining whether a cancer patient will respond to a class of therapeutics known as nucleoside prodrugs, according to Sofie.
The company also believes that FAC will be the first means available to image the activation of the immune system and the organ distribution of immune response to diseases, immunotherapies, infections and organ rejection over time.